Evaluation of methods for generating Senecavirus A virus-like particles utilizing the baculovirus expression vector system by English, Jennifer Lynn
Masthead Logo
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2017
Evaluation of methods for generating Senecavirus
A virus-like particles utilizing the baculovirus
expression vector system
Jennifer Lynn English
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Animal Diseases Commons, Molecular Biology Commons, and the Veterinary
Medicine Commons
This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital
Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital
Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
English, Jennifer Lynn, "Evaluation of methods for generating Senecavirus A virus-like particles utilizing the baculovirus expression
vector system" (2017). Graduate Theses and Dissertations. 16920.
https://lib.dr.iastate.edu/etd/16920
  
 
Evaluation of methods for generating Senecavirus A virus-like particles utilizing the 
baculovirus expression vector system 
 
 
by 
 
 
Jennifer Lynn English  
 
 
 
 
 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
MASTER OF SCIENCE 
 
 
Major: Veterinary Microbiology 
 
 
Program of Study Committee: 
James Roth, Co-major Professor 
Eric Vaughn, Co-major Professor 
Kenneth Stalder 
 
 
 
The student author, whose presentation of the scholarship herein was approved by the  
program of study committee, is solely responsible for the content of this thesis.   
The Graduate College will ensure this thesis is globally accessible  
and will not permit alterations after a degree is conferred. 
 
 
 
Iowa State University 
 
Ames, Iowa 
 
2018 
 
 
Copyright © Jennifer Lynn English, 2018.  All rights reserved.
ii 
 
 
TABLE OF CONTENTS 
                Page 
LIST OF TABLES ................................................................................................................... iii 
LIST OF FIGURES ................................................................................................................. iv 
NOMENCLATURE ................................................................................................................. v 
ACKNOWLEDGMENTS ...................................................................................................... vii 
ABSTRACT ............................................................................................................................. ix 
CHAPTER 1:  INTRODUCTION ............................................................................................ 1 
Background ........................................................................................................................... 1 
Objectives ............................................................................................................................. 1 
Thesis Organization .............................................................................................................. 2 
CHAPTER 2:  LITERATURE REVIEW ................................................................................. 3 
Characteristics of the Picornaviridae family ......................................................................... 3 
Seneca Valley Virus Genome ............................................................................................... 4 
Seneca Valley Virus Proteins Involved in Capsid Formation .............................................. 5 
Seneca Valley Virus Disease Characteristics ....................................................................... 6 
History of Seneca Valley Virus ............................................................................................ 7 
Current Scenario with Seneca Valley Virus ......................................................................... 9 
General Overview of Vaccine Approaches in the Animal Health Industry........................ 11 
VLP Vaccines ..................................................................................................................... 14 
Baculovirus Biology ........................................................................................................... 16 
Harnessing the Baculovirus Platform Technology for protein expression ......................... 17 
Successful application of the BEVS among the Picornaviridae ........................................ 20 
CHAPTER 3:  EXPRESSION AND PURIFICATION OF SENECA VALLEY VIRUS 
RECOMBINANT CAPSID PROTEINS FROM BACULOVIRUS-INFECTED INSECT 
CELLS .................................................................................................................................... 23 
Introduction ......................................................................................................................... 23 
Materials and Methods ........................................................................................................ 24 
Results ................................................................................................................................. 29 
Discussion ........................................................................................................................... 34 
CHAPTER 4: CONCLUSION ............................................................................................... 39 
APPENDIX: FIGURES, TABLES & EM IMAGES ............................................................. 41 
REFERENCES ....................................................................................................................... 56 
 
iii 
 
 
LIST OF TABLES 
                                                                                                                                       Page 
 
Table 1 Primer Sequences for SVVP1-His-SVV3C and SVVP1CO-His-SVV3C. 49 
 
Table 2  Primer Sequences for SVVP13C VP3/VP1 and SVVP13CD. .................. 49 
 
iv 
 
 
LIST OF FIGURES 
                                                                                                                                       Page 
 
Figure 1 Genome structure of picornavirus and polyprotein processing ................. 41 
 
Figure 2  Phylogenetic trees of the whole genome of SVA. ..................................... 41 
 
Figure 3 Seneca Valley virus baculovirus construct designs ................................... 42 
 
Figure 4  WSSV sIRES-split his-tagged SVVP1 with SVV3C baculovirus construct  
  designs........................................................................................................ 42 
 
Figure 5 SVVP13C VP3/VP1 and SVVP13CD baculovirus construct designs. ..... 43 
 
Figure 6 SVV Recombinant Capsid Protein Expression .......................................... 44 
Figure 7 Western blots of native SVV virus sucrose fractions and  
  BaculoFBU/SVVP13C sucrose fractions .................................................. 44 
 
Figure 8  Western blots of BaculoFBU/SVVP13C and BaculoFBU/SVVP13C  
  VP3/VP1 supernatant harvests. .................................................................. 45 
 
Figure 9 Western blots of BaculoFBU/SVVP13C VP3/VP1 sucrose fractions ....... 46 
 
Figure 10 Western blots of BaculoFBU/SVVP13CD Supernatant Harvest .............. 46 
 
Figure 11 Western blots of BaculoFBU/SVVP13CD sucrose fractions. ................... 47 
 
Figure 12 Western blots of BaculoFBU/SVVP13C, BaculoFBU/SVVP13CD and 
BaculoFBU/SVVP13C VP3/VP1 Day 3 Soluble Fractions ...................... 47 
 
Figure 13 Western blots of sucrose fractions of Day 3 Soluble BaculoFBU/SVVP13C, 
BaculoFBU/SVVP13CD and BaculoFBU/SVVP13C VP3/VP1 .............. 48 
 
 
 
v 
 
 
NOMENCLATURE 
AcNPV  Autographa californica Nuclear Polyhedrosis Virus 
ADG   Average Daily Gain 
BEVS   Baculovirus Expression Vector System 
BV   Budded Virus 
CVA   Coxsackievirus A 
DIVA   Differentiation of Infected from Vaccinated Animals 
DNA   Deoxyribonucleic Acid 
EMCV   Encephalomyocarditis Virus 
EM   Electron Microscopy 
ETNL   Epidemic Transient Neonatal Losses 
EV71   Enterovirus 71 
FMD   Foot-and-Mouth Disease 
FMDV   Foot-and-Mouth Disease Virus 
HAV   Hepatitis A Virus 
IRES   Internal Ribosomal Entry Site 
ISU VDL  Iowa State University Veterinary Diagnostic Lab 
kDa   Kilodalton 
NADC   National Animal Disease Center 
NT   Nucleotides 
ODV   Occlusion-derived Viruses 
OIE   Office International des Epizooties 
ORF   Open Reading Frame 
vi 
 
 
PCR   Polymerase Chain Reaction 
PTM   Post-translational Modifications 
RNA   Ribonucleic Acid 
RT-PCR  Reverse Transcription Polymerase Chain Reaction 
SIVD   Swine Idiopathic Vesicular Disease 
SVD   Swine Vesicular Disease 
SVDV   Swine Vesicular Disease Virus 
SVV   Seneca Valley Virus 
TBS   Tris-buffered Saline 
TEM   Transmission Electron Microscopy 
USDA   United States Department of Agriculture 
UTR   Untranslated Region 
VE   Vesicular Exanthema 
VEV   Vesicular Exanthema Virus 
VS   Vesicular Stomatitis 
VSV   Vesicular Stomatitis Virus 
VLP   Virus-like Particle 
VPg   Viral Protein, genome linked 
vii 
 
 
ACKNOWLEDGMENTS 
I would like to thank my Co-major professors Dr. Eric Vaughn and Dr. James Roth 
for their guidance and expertise throughout the scientific and writing process of the work 
contained in this thesis.  Dr. Vaughn has shown complete support from beginning to end, and 
I appreciate his trust and confidence in my abilities for completing this milestone in my 
career.  Dr. Roth agreed to be a Co-major professor as I enrolled as an untraditional graduate 
student.  He has put in much effort in assisting with the requirements of the graduate program 
with little in return; if it was not for him, I would not have been able to start and complete 
this degree.  I, also, owe a huge thank you to Dr. Ken Stalder for not only serving as a 
committee member for my Master’s, but for being the first professor when I was an 
undergraduate to realize my potential as a graduate student and encouraging me to further my 
education.      
I would like to express my gratitude to all of those at BIAH who have worked with 
me on many different levels to reach this accomplishment.  Luis Hernandez is an outstanding 
mentor and is always challenging me to improve as a scientist.  I could not have done this 
without his guidance and support.  Scott Ackerman was a great team player assisting me with 
lab work when I had to run off to class.  Arun Iyer spent many hours of his personal time 
providing constructive revisions and advice during the review process of my thesis, as well 
as, continually checking in on my progress and providing encouragement.  I am thankful to 
work with such a supportive group of colleagues within a company that believes in personal 
development.   
Lastly, I would like to thank my family and friends for their love and support on the 
home front.  They have downloaded countless articles I needed for my thesis, provided me 
viii 
 
 
with meals, dog sat my beloved Bella and Daisy and have been understanding in my lack of 
presence, especially in these last few months.  I am very grateful to have been given such a 
great opportunity for my personal development and professional career. 
 
ix 
 
 
ABSTRACT 
 A recombinant subunit vaccine against Seneca Valley virus (SVV) would be valuable 
to the swine industry.  Recent SVV outbreaks have raised concerns with national biosecurity.  
This is due to the potential of foreign vesicular animal diseases entering the United States 
undetected because of confounding clinical signs of SVV.  Research with the baculovirus 
expression vector system (BEVS) has produced virus-like particles (VLP) that elicited 
neutralizing antibodies and protected against challenge for many Picornaviridae viruses.  
Building on this previous research, attempts of SVV VLP assembly for a vaccine candidate 
were performed using the BEVS.   
 All baculovirus constructs were designed to encode the SVV P1 region, 2A protease, 
portions of the 2B and 3B genes and 3C protease.  Recombinant SVV proteins VP1, VP2 and 
VP3 were expressed in several baculovirus construct iterations.  Peptide specific antibodies 
detected each protein by means of Western blot analysis.  Sucrose gradient fractionation and 
electron microscopy (EM) were performed to verify VLP formation.  However, VLP 
production was not confirmed by either method.   
 Several factors influence the assembly of SVV VLPs.  One outcome providing insight 
of the complete cleavage of the recombinant capsid proteins is the identification of a 55kDa 
protein band.  This band was detected in the α-SVV VP1 and α-SVV VP3 Western blots.  
Also, the 3C protease and its impact in the BEVS need further investigation to determine its 
role in complete cleavage of the recombinant capsid proteins.  Lastly, there were indications 
the recombinant capsid proteins were aggregating instead of folding properly into VLPs.  The 
gaps in information noted here support the need for further research into capsid formation in 
Picornaviridae viruses to improve VLP assembly using the BEVS.      
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CHAPTER 1:  INTRODUCTION 
 
Background 
Seneca Valley virus (SVV) is the common virus name for the Senecavirus A species  
which is the only species within the Senecavirus genus in the Picornaviridae family1.  The 
Picornaviridae family also includes the foreign animal disease viruses, Foot and Mouth 
Disease Virus (FMDV) and Swine Vesicular Disease Virus (SVDV).  Pigs infected with 
SVV, FMDV or SVDV present similar clinical signs of fluid filled vesicles on the snout and 
coronary bands of the hoof.  Seneca Valley virus has circulated in US herds for many years, 
but recent outbreaks with clinical signs have raised concerns with biosecurity.  Inadvertently 
allowing FMDV or SVDV to enter US swine herds due to under reporting of SVV would be 
devastating to the swine industry.  Providing a vaccine for SVV would reduce the prevalence 
of vesicle presentation in swine in turn decreasing the risk of failing to comply in the 
reporting of vesical clinical signs.  This would support rapid identification of harmful foreign 
diseases of swine exhibiting similar clinical signs. 
 
Objectives 
 The objectives of this research were to: 1. Design and engineer baculovirus constructs 
encoding SVV capsid proteins.  2.  Evaluate the expression of the SVV recombinant capsid 
proteins in baculovirus-infected insect cells.  3. Assess the SVV recombinant capsid proteins 
from baculovirus-infected insect cells for VLP formation by sucrose gradient fractionation 
and electron microscopy (EM) imaging. 
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Thesis Organization 
 This thesis consists of an introduction, literature review, one original research chapter 
and a conclusion.  Chapter 1 serves as the introduction followed by the literature review in 
Chapter 2.  Topics included in the Chapter 2 literature review begin with the overall 
characteristics of the Picornaviridae family then discuss in more detail the genome, capsid 
formation, disease, history and current status of Seneca Valley virus.  The literature review 
also covers a general overview of vaccine approaches in the animal health industry, VLP 
vaccines, baculovirus biology, harnessing the baculovirus platform technology for protein 
expression and successful application of the BEVS for VLP assembly of Picornaviridae 
proteins.  Chapter 3 contains original research for designing and constructing baculovirus 
constructs for expression and assembly of SVV VLPs.  Chapter 4 consists of a conclusion 
summarizing the material presented.  The author’s role in this research included the assembly 
of baculovirus constructs, purposeful genetic manipulation of gene fragments, PCR 
screening, transfection and harvest of baculovirus infected insect cells, evaluation of 
expressed proteins by SDS-PAGE and Western blotting, analysis and interpretation of results 
and manuscript writing.   
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CHAPTER 2:  LITERATURE REVIEW 
 
Characteristics of the Picornaviridae family 
The Picornaviridae family currently consists of 35 genera including Senecavirus 2.  
Picorna is derived from pico meaning small and RNA referring to the RNA genome that all 
family members possess 3.  Viruses in this family have a viral capsid that surrounds the 
positive-sense, single-stranded RNA genome that is approximately 7500-8500 nucleotides 
(nt) 4,5.  A single open reading frame (ORF) encodes for structural proteins located at the 5’ 
end and proteins responsible for protein processing and viral replication encoded at the 3’ 
end 6.  The ORF is translated into a single polyprotein that is cleaved into the individual 
functional proteins 4,5.  Covalently attached at the 5’ N-terminal end of the genome is a viral-
encoded protein VPg that is responsible for initiation of RNA synthesis followed by a 5’ 
untranslated region (UTR) 4,5.  In this UTR, an internal ribosome entry site (IRES) is present 
which allows RNA translation to occur in a cap-independent manner 5. 
After the 5’ UTR, many picornavirus genera have a standard L-4-3-4 protein layout 
consisting of a Leader protein-P1 region with 4 polypeptides-P2 region with 3 polypeptides-
P3 region with 4 polypeptides (Fig. 1) 2,5-7.  The P1 region encodes for the icosahedral viral 
capsid that contains 60 copies of VP1 and VP3 subunits, 58-59 copies of VP2 and VP4 
subunits and one or two copies of VP0, a precursor protein of VP2 and VP4 2,4,8,9.  However, 
there are several picornavirus genera where VP0 remains uncleaved in the final capsid 
structure 2.  The P2 and P3 regions encode nonstructural proteins 2A, 2B, 2C, and 3A-3D for 
protein processing and viral replication 2.  The 2A, 3C and 3C-precursor proteins are 
responsible for cleaving the single polyprotein resulting in the functional subunit proteins.  
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The 2A protease cleaves the structural proteins from the nonstructural and 3C and 3C-
precursors complete the other cleavages.  The orthologous proteins 1B, 1C, 1D, 2C, 3C and 
3D are conserved in all picornaviruses while 1A, 2A, 2B, 3A and 3B are highly divergent 
among Picornaviridae genera 2.  The replication cycle of these viruses rapidly occurs in the 
cytoplasm with nonstructural viral proteins contained in replication organelles and host cell 
machinery 2,5.  
 
Seneca Valley Virus Genome 
Seneca Valley virus is a small (27-30 nm), non-enveloped virus belonging to the 
Senecavirus A species within the Picornaviridae family 6,10.  Three clades have been 
identified using phylogenetic analysis of SVV VP1: clade I contains the historical strain 
SVV-001, clade II contains USA SVV strains identified between 1988 and 1997, and clade 
III contains global SVV strains from Brazil, Canada, China, and the USA identified between 
2001 and 2015 (Fig. 2) 11.  In regards to other Picornaviridae viruses, Senecavirus A is most 
closely related to the Cardioviruses based on complete genome sequence analysis 6,12,13.    
In 2008, the SVV-001 genome was determined to contain 7280 nt which is predicted 
to contain 666 nt of  UTR at the 5’ end followed by an ORF of 6543 nt encoding a 2181 
amino acid polyprotein, a 71 nt 3’ UTR and ending with a poly(A) tail 6.  The polyprotein is 
divided into three polypeptides: P1, P2 and P3 that are further cleaved into eleven proteins in 
the standard Picornaviridae L-4-3-4 layout 7.  The P1 region encodes the structural proteins 
VP0, VP3 and VP1 that make up the viral capsid while the P2 and P3 regions encode 
nonstructural proteins 2A, 2B, 2C, 3A, 3B, 3C and 3D which are responsible for protein 
cleavage and viral replication.  The VP0 precursor protein is presumed to be cleaved into 
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VP4 and VP2 due to the start of the P1 region occurring 71 residues upstream of the 
predicted VP2 sequence 6.   
 
Seneca Valley Virus Proteins Involved in Capsid Formation 
 The SVV P1 polyprotein is processed by self-cleaving proteases to form individual 
viral capsid subunit proteins VP1-VP4.  The 3C viral protease separates VP0, VP3 and VP1 
proteins from each other to form an intermediate protomer.  This protomer further assembles 
into 12 pentamers forming an icosahedral capsid.  The VP0 protein is predicted to cleave into 
VP4 and VP2 during a maturation cleavage involving RNA encapsidation 2.  On the external 
surface of the viral capsid VP1, VP2 and VP3 proteins are exposed while VP4 is internal 11.  
The N-terminal sequences of the three major structural proteins VP1, VP2 and VP3 have 
been determined with amino acid sequencing.  Based on the N-terminal sequences, the 
predicted cleavage sites of VP4/VP2/VP3/VP1 are Lys/Asp, Gln/Gly and His/Ser, 
respectively 6.   
The SVV 3C protease responsible for cleaving VP0, VP3 and VP1 is a chymotrypsin-
like enzyme with a cysteine in place of a serine in the catalytic site 14,15.  Many active-site 
residues and amino acid motifs of SVV 3C protease are conserved with other known 
picornavirus 3C three-dimensional structures 11,16.  Predicted cleavage sites for SVV are 
typical of picornavirus 3C proteases, where cleavage occurs at Gln/Gly, Gln/Ser or Glu/Asn 
residues 4.  Two atypical cleavage sites include the His/Ser between VP3 and VP1 and 
Gln/Gln or Gln/Pro between 3B and 3C 6. 
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Seneca Valley Virus Disease Characteristics 
Seneca Valley virus has been associated with swine idiopathic vesicular disease 
(SIVD) which is characterized by coalescing erosions, ulcerations and vesicular lesions on 
the snout, oral cavity and coronary bands of the hoof, interdigital area, dewclaws and hoof 
pads 17-19.  The lesions first appear as swollen areas that evolve to vesicles, which rupture 
quickly and form ulcers that may be covered by a serofibrinous exudate 11.  Ulcers begin 
healing within seven days and generally healed in two weeks.  Scarring is possible if lesions 
are severe, but is not observed in all cases.  Other clinical signs from SVV outbreaks have 
included crusting and sloughing of the hoof wall as well as lameness 11,20.  No other gross or 
microscopic lesions have been observed in affected animals 11.  Other general signs are fever, 
lethargy and anorexia 11,19.  In recent SVV outbreaks, neonatal piglets 1 to 4 days of age 
experienced higher rates of mortality, severe diarrhea, dehydration and lethargy 19,21.   
While there has been an increase in SVV-associated SIVD, it is not a debilitating 
disease and mild compared to other foreign vesicular diseases 11,22.  The major risk factor of 
SVV is the indistinguishable clinical signs it shares with vesicular foreign animal diseases 
Foot-and-mouth disease (FMD), Swine vesicular disease (SVD), vesicular stomatitis (VS) 
and vesicular exanthema of swine (VE), not the disease itself 11,19,22.  It also shares clinical 
signs with porcine enterovirus group III infection, parvovirus infection, mycotoxicosis, 
chemical burns and photodermatitis associated with the consumption of celery, parsnips, or 
carrots infested with the fungus Sclerotinia sclerotiorum 22.   
Seneca Valley virus clinical signs could have a large impact on the pork industry due 
to the similarity to FMD, which is on the Office International des Epizooties (OIE) disease 
list.  Clinical signs of vesicular lesions must be reported to regulatory authorities so an 
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investigation can be initiated.  Samples are collected for testing to rule out more debilitating 
diseases such as FMD.  During the investigation, animal movement is banned, human 
movement is restricted and animals may be culled to reduce the risk of spreading disease.  
Besides the confounding clinical signs of SVV, lameness caused by lesions on the coronary 
bands can also decrease eating leading to a decrease in average daily gain (ADG), decrease in 
final market weight, or increase in days to market which all affect profitability.   
The majority of SVV cases occur between spring and fall months 22.  In general, 
transmission of picornaviruses is linked to direct contact with infected individuals, fecal-oral, 
fomite or airborne routes 2,17.  A specific route of transmission for SVV has not been 
identified, but general biosecurity measures should be enforced to reduce potential 
introduction of the virus 17.  Rodents are suspected to be possible carriers due to neutralizing 
antibodies detected previously in mice 12.  Rodents have also been implicated as reservoirs 
for encephalomyocarditis virus (EMCV) which belongs to the closely related Cardiovirus 
genus 23.  Seneca Valley virus has been identified in healthy pigs displaying no clinical signs 
of infection; however, experimental studies with SVV obtained from infected pigs have 
produced vesicular disease 24-26.  
 
History of Seneca Valley Virus 
In 2002, SVV-001 was isolated at Genetic Therapy Inc. near Seneca Creek State Park 
(Gaithersburg, MD, USA) where it was found accidentally as a cell culture contaminant 
6,11,12.  It is believed to have originated from cell-culture medium from either contaminated 
porcine trypsin or fetal bovine serum.  Since the sequencing of this prototype strain, at least 
twelve virus isolates from pigs in the United States have been submitted to the National 
8 
 
Veterinary Services Laboratory and identified to be serologically similar 6.  Between 1988 
and 2005, seven isolates were identified as SVV using pan-picornavirus RT-PCR 12.  Isolates 
were collected from Minnesota, North Carolina, Iowa, New Jersey, Illinois, Louisiana, South 
Dakota and California.  Seneca Valley virus is a relatively new virus in swine herds in the 
U.S. based on evolutionary analyses of the virus.  It has also been identified in other 
countries such as Canada, China and Brazil10,17.    
Generally, interest in SVV has been directed more towards its oncolytic properties for 
human cancer treatments rather than its disease etiology in pigs 27-33.  Oncolytic viruses like 
SVV are replication-competent viruses that selectively cause cytotoxicity in cancer cells 
without excessively damaging normal tissues 11,29,32.  A great deal of research has been done 
with SVV in treating neuroendocrine cancers including clinical trials 34,35.  Although most of 
the research for SVV is focused on its oncolytic properties, there have been some clinical 
reports of disease in swine linked to SVV.  
 In 2007, a group of 187 pigs brought to Minnesota from Canada had twelve pigs with 
apparent lesions indicative of vesicular disease and at least 80% were considered lame 22.  
Tests for FMDV, SVD, VSV and VEV were all negative.  The presence of porcine circovirus 
and porcine enterovirus were reported by the United States Department of Agriculture 
(USDA) while SVV was discovered soon after with further testing.  In addition, a boar in 
Indiana presented clinical signs for vesicular disease and tested positive for SVV while other 
vesicular diseases were ruled out in 2010 18.  Seneca Valley virus was also confirmed in three 
cases by a swine veterinarian in North Carolina in 2012 by RT-PCR and virus isolation 36.  
However, due to these low numbers of identified cases in the past there has been little 
interest in SVV until recent increased outbreaks and implications with SIVD.  
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Current Scenario with Seneca Valley Virus 
 There has been a spike in SVV cases in several different countries around the world 
including the US in the last two to three years leading swine veterinarians to classify SVV as 
an emerging infectious disease 37.  In the past three years, SVV has been confirmed in Brazil, 
China and Thailand by RT-PCR of RNA extracted from field samples 7,10,38.  In the US, three 
cases in Iowa and one case from South Dakota were submitted for swine vesicular disease 
and tested positive for SVV 39.  These recent cases prompted Veterinary Diagnostic Labs at 
Iowa State University and University of Minnesota to retrospectively test approximately 
1000 oral fluid samples from swine not exhibiting clinical signs of SVV 37.  Samples from 
numerous states tested PCR positive indicating widespread areas of infection 37.   
The current circulating SVV strains are more closely related to each other than to 
historical strains, and can be categorized into two groups with one containing relatively mild 
strains that display vesicular lesions and another with more aggressive strains associated with 
lameness and piglet mortality 39,40.  In November 2014, farms in Brazil reported pigs with 
vesicles and lesions on the snouts and coronary bands, neonatal pig mortality and self-
limiting outbreaks lasting 1-2 weeks 21.  A unique observation of the SVV cases in Brazil 
was the neonatal piglet mortality recently described as epidemic transient neonatal losses 
(ETNL) syndrome.  Piglet mortality in the first four days of life was between 30-70% with 
SVV identified by PCR in the lung, heart, liver, spleen, kidney and intestinal tissues 21.  
Samples were submitted to the University of Minnesota Veterinary Diagnostic Laboratory 
from vesicles and sera of pigs displaying signs of vesicular disease.  Three complete genome 
sequences were constructed from the samples and showed 99.5% nucleotide identity 21.  
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Based on phylogenetic trees, these sequences were most closely related to a Canadian 
strain21.   
In July and August of 2015, three Iowa swine farms had several cases of vesicular 
disease in sows showing lesions on coronary bands of the hoof and nostrils lasting for no 
more than 10 days 19,20,41.  An increase in mortality to 30-40% was observed in neonate 
piglets which paralleled the mortality rates reported with the SVV cases in Brazil 19,20.  One 
field study determined that SVV seropositive sows could transfer maternal antibodies to their 
offspring.  They also noted SVV-VP1 IgG antibodies in sows increased the first three weeks 
following clinical signs of outbreak in conjunction with decreased detectable levels of SVV 
in the sera.  These finding suggest possible neutralizing capabilities of the SVV-VP1 
antibodies due to reduced viremia in the presence of the SVV-VP1 antibodies 19.  In other 
Picornaviridae viruses such as FMDV and Enterovirus 71 (EV71), VP1 is described as the 
most immunogenic capsid protein due to several neutralizing antibodies identified against 
epitopes located on it 9,19,42-44.   
To date, all SVV-positive vesicular disease outbreaks have tested negative for other 
vesicular diseases.  The increased number of cases for SVV-associated idiopathic vesicular 
disease in swine triggered Iowa State University Veterinary Diagnostic Lab (ISU VDL) to 
test other submitted samples describing clinical signs associated with the presence of SVV.  
From July 2015 to  September 2017, more than 230 cases of SVV have been confirmed 
across all swine production sites, as well as, exhibition pigs and a truck wash 45,46.  The 
USDA has labeled SVV as a new, emerging swine disease that is active in the industry 40, 
and the Center for Food Security and Public Health has stated that methods for preventing 
and controlling SVV are lacking with no vaccines currently available 17.     
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General Overview of Vaccine Approaches in the Animal Health Industry 
 The concept for vaccination gained popularity in the late 18th century when Edward 
Jenner, the pioneer of vaccines, created the world’s first vaccine for smallpox 47.  Jenner’s 
discovery was instrumental in defining the fundamental principles for the development of 
human and animal vaccines.  Vaccines are the most effective way to control disease today 48.  
Conventional methods consist of inactivated and live attenuated vaccines.  Inactivated virus 
vaccines are prepared by inactivating the virus with heat, chemicals or radiation and may be 
combined with an adjuvant to boost the immune response 49-51.  This type of vaccine is 
typically safer and more stable than the live attenuated vaccine 52.  However, inactivated 
vaccines generally stimulate a weaker immune response compared to live attenuated vaccines 
and may require booster shots to achieve optimal immunity 53,54.  
Live attenuated vaccines are weakened versions of the natural disease-causing virus; 
therefore, they are also the most similar to the natural virus.  Attenuation is commonly 
achieved by serial cell-culture passage of the virus in cell cultures derived from heterologous 
species.  This encourages adaptations that render the virus unable to induce clinical disease in 
the natural host 49.  Chemical mutagenesis reagents can also be added to increase mutations 
during cell-culture passage.  The advantage of live attenuated vaccines is the strong cellular 
and humoral host responses elicited against viral infection 54.  However, there is the risk for 
the vaccine virus to mutate and revert to virulence 53.  This is a major concern for those 
diseases that can have huge impacts on the animal industry such as FMD.  With the increase 
in molecular research, opportunities to address the concerns of conventional vaccines show 
great potential for innovative approaches to vaccine design. 
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Innovative technology vaccines such as DNA vaccines, subunit vaccines and 
recombinant vector vaccines are becoming increasingly important with the need to have 
vaccines that are safe and effective 50.  In addition to the safety and efficacy of vaccines, it 
must be kept in mind that production costs and ease of administering vaccines are also major 
factors in the animal industry.  Potential for differentiation of infected from vaccinated 
animals (DIVA) is an approach DNA, subunit and recombinant vector vaccines can utilize.  
This technique is often not available when using inactivated or live attenuated vaccines 50.  
This aids as a tool for animal caretakers and veterinarians for disease surveillance and 
eradication programs with vaccine use.  These alternative technology vaccines also allow for 
flexibility and variety of vaccine design with DNA manipulation providing opportunities to 
express single and multiple antigens from the same or different pathogens.   
DNA vaccines are simple and inexpensive to produce while providing target 
specificity of immune responses.  DNA vaccines are designed to incorporate specific 
antigenic genes of a virus that the immune system responds to as if induced by the replication 
of a live pathogen 55.  Immunization with a DNA vaccine converts the host cells into vaccine 
antigen-making factories, translating the viral genes then displaying the antigens on their cell 
surface or secreting them into the extracellular space resulting in a strong antibody and 
cellular response 55.  Two licensed veterinary DNA vaccines are West Nile-Innovator® DNA 
for horses and APEX-IHN® approved by the Canadian Food Inspection Agency to prevent 
Infectious Haematopoietic Necrosis (IHN) in farm-raised salmon 55.  In a mouse model, a 
DNA vaccine containing the P12A3C genome of EMCV elicited neutralizing antibodies, 
protected against challenge and was comparable to a commercial vaccine 56.  There was also 
evidence of increased cytokine levels for IL-2, TNF-α, GM-CSF, IL-4 and IL-10 56.  Studies 
13 
 
conducted in swine with vaccines encoding a surface glycoprotein for classical swine fever 
virus (CSFV) and pseudorabies virus (PRV) resulted in protective immune responses as 
well55.  The major disadvantage of DNA vaccines is the large amounts of DNA needed for an 
effective response in animals 55.  Improvements in plasmid uptake, adjuvants, different routes 
and modes of administration are all approaches that are being investigated to improve the 
efficacy of DNA vaccines 55.   
Subunit vaccines are made up of specific antigens that have been produced and 
purified from the virus or generated using DNA technology prior to vaccine formulation 49.  
Subunit antigens are administered without viral replication occurring in the host 55.  In 
general, immunogenicity derived from subunit vaccines may require higher doses, booster 
administrations and adjuvants to achieve protection comparable to that induced by live 
attenuated vaccines 43,48.  One of the first examples of this technology was in the 1970’s 
when scientists discovered that a vaccine made up of a single key protein of FMDV could 
potentially protect against the disease 57.  In 1981, Kleid and colleagues were able to express 
the VP3 of FMDV in Escherichia coli and prepare the world’s first ever genetically 
engineered vaccine for use in cattle and swine 42. 
 Recombinant viral vector vaccines use an attenuated virus to present the antigen of 
interest to the animal to evoke an immune response 49.  Research has shown the recombinant 
adenovirus vector containing picornavirus EMCV P1 with 2A and 3C proteases produced 
neutralizing antibodies against VP1 in mice and protected against challenge 23.  The first 
licensed vaccines using this technology protect against hepatitis B Virus (HBV) and human 
papillomavirus (HPV) 58.  Both vaccines are very successful and often used as the gold 
standard for comparison with other recombinant vector vaccines.  This type of genetically 
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engineered vaccine has combined many advantages of the conventional and innovative 
technologies making it a highly sought after method for producing safe and efficacious 
vaccines 50.   
 
VLP Vaccines 
 Another group of genetically engineered vaccines are virus-like particles (VLPs) that 
form empty capsids resembling the appearance of native virus externally, but do not contain 
genetic material 55,59.  Virus-like particles present an array of relevant epitopes similar to 
those of infectious virions 60,61.  Continuous and discontinuous antigenic sites presented by 
VLPs elicit immune responses comparable to killed virus vaccines 9,62.  Virus-like particles 
can induce strong humoral and cellular immune responses due to the repetitive antigenic 
proteins that lead to crosslinking of B cell immunoglobulin receptors and B cell activation 48.  
The antigens are also taken up by dendritic cells which in turn stimulate CD4+ cells to react 
to the VLP 48,55.  Several studies have demonstrated these strong humoral and cellular 
immune responses in different animal species with administration of VLPs through various 
routes such as intranasal, intramuscular and intraperitoneal 61,63.  Antigens from 
picornaviruses such as FMDV, EMCV, EV71, coxsackievirus A (CVA), and hepatitis A 
(HAV) have been expressed as VLPs and shown to confer neutralization and/or 
protection23,44,62,64-66. 
Several features of VLP vaccine technology deem it safer compared to traditional 
inactivated and live attenuated vaccines 61,67.  These include a reduced risk of adverse 
reactions, lack of replication, no reversion to virulence and no possibility of vaccine-
associated outbreaks.  Virus-like particle vaccines also have DIVA marker potential to 
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differentiate infected animals from vaccinated animals since antibodies are not generated 
against internal and non-structural viral proteins 55.  Compared to DNA and subunit vaccines, 
the strong immune responses elicited by VLPs make it a preferred vaccine platform 49,67.  The 
capability to quickly switch out strain sequences in response to evolving viruses is also an 
advantageous feature of the VLP vaccine platform.  Additionally, the VLP molecular 
platform can be modified to display viral epitopes of a heterologous virus boosting 
immunogenicity of the specific epitope and creating a multivalent vaccine 44,55,58,61,67.   
Expression systems that generate VLPs have different characteristics to take into 
consideration when choosing the production platform.  The E.coli expression system is the 
most widely used platform for recombinant proteins due to easy scale-up and high expression 
yields 63,68,69.  However, bacteria lack the ability for proteins to undergo post-translational 
modifications (PTM) making it the least versatile of the VLP expression systems 48.  For this 
reason, it works best with simple, non-envelope proteins 44.  The other expression systems 
are eukaryotic which allow for PTM at varying levels.  Yeast provides easy scale-up and high 
expression yields of VLPs, and in addition allows PTM to occur 70-72.  However, the sugar 
residues used in glycosylation by yeasts are different from those used by mammalian cells.  
The mammalian cell expression system’s greatest advantages are the ability for recombinant 
proteins to undergo PTM and the assembly of complex, multi-protein VLPs 73,74.  
Conversely, the production cost of using mammalian cells is the highest of the expression 
platforms.  Plant biotechnology has opened up the possibility of expressing VLPs in plants 
with low cost processing, easy scale-up and increased safety since plants are free of animal 
diseases 55,75,76.  A plant-based system is similar to yeast, mammalian, and insect expression 
systems with the ability to express VLPs from non-envelope and envelope proteins that 
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undergo PTM 48.  Plant-based systems also provide a means of administering the vaccine by 
direct ingestion of the plant.  Despite the easy scale-up and ease of administration for plant-
based VLPs, issues with VLP assembly, stability, antigen degradation during in vivo delivery 
and low expression levels need to be addressed 55,57,76.  The baculovirus expression vector 
system (BEVS) has been described as the most powerful and versatile eukaryotic expression 
system for producing complex, multi-protein VLPs 77.  The BEVS uses insect cells infected 
by recombinant baculovirus to express antigens of interest 67.  Insect cells have an 
accelerated metabolism ideal for producing high protein yields 55.  The BEVS also provides 
production versatility, scalability, efficiency and speed of vaccine development 55,67. 
 
Baculovirus Biology  
Baculoviruses belong to the Baculoviridae family, and are large (80-200Kb), double-
stranded, circular DNA viruses that infect many species of insects 77,78.  The enveloped, rod-
shaped nucleocapsid can accommodate large amounts of foreign DNA which led to the wide 
use of these viruses as recombinant vectors 67,77-79.  Originally, the wild-type baculovirus 
Autographa californica nuclear polyhedrosis virus (AcNPV) was used for co-transfection 
with recombinant transfer vectors 79.  This method took a considerable amount of time and 
effort for screening and selecting recombinant baculovirus particles with only 0.1% 
recombination frequency 77,80.  This led to the modification of AcNPV and Bombyx mori 
nucleopolyhedrovirus genomes for research purposes to generate insect cell-derived vaccines 
with AcNPV being the most widely used 55,59,78. 
Infectious AcNPV enters susceptible insect cells by facilitated endocytosis or fusion.  
Viral DNA is uncoated in the nucleus and replication starts to take place six hours after the 
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baculovirus infects the host cell 77.  Occlusion-derived viruses (ODV) are important for 
horizontal transmission of disease and are assembled in a crystalline protein matrix within 
the nucleus 78.  In wild-type AcNPV the ODV develop during the very late phase of gene 
expression 78.  This is usually around three days post infection and continue to accumulate 
until five or six days post infection 77.  These occluded virus particles are primarily made up 
of the polyhedrin protein, and are released by cell lysis 77,78.  Increasing amounts of 
polyhedrin protein during the very late phase of infection may account for 30-50% of the 
total insect cell protein 77.  Secondary infection is denoted by extracellular virus particles that 
bud from the cell membrane of infected cells and are referred to as budded viruses (BV) 78.  
They are produced during the late phase of gene expression and are responsible for cell-to-
cell infection 78.  The BV is exploited in the BEVS for foreign protein expression. 
 
Harnessing the Baculovirus Platform Technology for protein expression 
The BEVS has several features that make it the workhorse of expression systems.  It 
is simple to use, allows for large foreign protein inserts, multiple gene expression, signal 
peptide cleavage, intron splicing, nuclear transport, functional proteins, and PTM 59,77,78,81.  
The baculovirus genome is modified with restriction sites that are utilized to delete sections 
of essential genes.  This linearizes the baculovirus genome facilitating the homologous 
recombination with transfer vectors containing a gene or genes of interest.  This in turn 
restores the lethally deleted virus and creates a viable recombinant baculovirus 77,80,82.  
Transfer vectors are most often utilized for insertion of heterologous genes as the large size 
of the baculovirus genome makes in vitro manipulation difficult 77.  Homologous 
recombination of the baculovirus and plasmid occurs in insect cells that are susceptible to 
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baculovirus infection such as Sf9 and Sf21 cells.  These cells were originally established 
from ovarian tissues of Spodoptera frugiperda larvae 77,78.  After 3-5 days the homologous 
recombined baculovirus is harvested with 99% efficiency 77. 
The polyhedrin gene is the primary location for heterologous gene insertion because 
the protein is produced in large amounts in the native virus.  It is also nonessential for the 
baculovirus life cycle in tissue culture 77-79.  Many baculovirus transfer vectors have been 
designed with the AcNPV genome to switch out the polyhedrin gene for a heterologous gene.  
The pVL1392 and pVL1393 vectors have been used extensively with the baculovirus 
platform and are based on the polyhedrin locus 77.  These vectors contain an E.coli origin of 
replication, an antibiotic resistance marker, the polyhedrin gene promoter region, a multiple 
cloning site to insert the gene or genes of interest, and AcNPV sequence flanking the cloning 
site to enable homologous recombination 77.   
Although the polyhedrin locus is most extensively used, other loci are capable of 
modification for heterologous protein insertion.  The decision to use different loci is 
determined based on whether the timing of protein expression during the viral infection cycle 
is important.  Baculovirus-encoded promoters can be divided into four different types based 
on the chronological order in which they are activated 77,78.  Immediate early promoters are 
activated by and control early viral transcription factors while delayed early promoters 
control genes necessary for viral replication, and thus are activated before viral DNA 
synthesis occurs 77,78.  The immediate early or early promoters are typically not used for 
heterologous genes due to their essential roles in the virus life cycle and their overall weak 
expression during the baculovirus infection cycle 83.  Late promoters are active during and 
after viral DNA synthesis and control genes necessary to assemble virus particles 83.  Very 
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late promoters are not activated until after viral assembly is complete and control genes 
responsible for the formation of occlusion bodies and cell lysis 77,78.  The late and very late 
promoters are commonly used in baculovirus transfer vector design because they drive strong 
protein expression 67,77-79.  The polyhedrin and p10 promotors are examples of very late 
promoters that can be utilized together in transfer vectors to express two different proteins 
simultaneously 81,84.   
Recombinant protein is produced by the baculovirus taking over insect cell machinery 
and shutting off host gene expression 77,78.  The recombinant virus continues to infect 
additional insect cells, which results in additional recombinant protein produced.  
Baculovirus-expressed proteins are typically recovered from the same sub-cellular 
compartments as the native protein unless additional sequence is added such as a signal 
sequence that direct the protein to be secreted 77.  Recombinant protein production can reach 
up to 30%-50% of the total insect cell protein produced, but amounts vary based on the 
properties of each individual protein and number of promoters utilized 77,85.   
One disadvantage of the BEVS is the inherent coproduction of baculovirus particles, 
which can affect antigen yields.  Baculovirus particles also may interfere with the VLP-
specific immune response of the host possibly decreasing vaccine effectiveness 59.  Either a 
chemical inactivation has to be performed in order to eliminate baculovirus infectivity, or 
several downstream processing steps must be performed 67.  Both methods have the potential 
to impair VLP quality, quantity and stability 57.   
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Successful application of the BEVS among the Picornaviridae  
The BEVS system is an ideal expression system for vaccine development for 
picornaviruses given they naturally form immunogenic, empty viral capsids 86.  Several 
picornaviruses including EV71, Poliovirus and FMDV exhibit empty viral particle capsids 
during natural infection 9,87-89.  These empty capsids do not contain viral genomic RNA and 
therefore are non-infectious.  In several studies, these naturally occurring empty capsids have 
been shown to be antigenically similar in immunological and serological tests when 
compared to native virus containing RNA 65,86,87,90.  Expressing VLPs using the BEVS for 
vaccine development provides options to control and manipulate the design of the empty 
capsid for increased stability, immunogenicity, expression levels, and opportunities for 
chimeric VLPs to protect against different strains or types of viruses 59.  Several approaches 
for expressing VLPs in the baculovirus system have been evaluated for different 
picornaviruses.  However, to the best of my knowledge no published work to date has been 
shown successfully expressing SVV VLPs.   
One approach to baculovirus construct design is to insert the complete ORF of a virus 
for VLP expression.  The translation of HAV and poliovirus ORFs has led to protein VLP 
assembly that has elicited neutralizing antibodies in mice 66,91.  Several other baculovirus 
constructs have been designed to co-express only the picornavirus genes that encode the 
capsid proteins and picornavirus proteases such as 2A, 3C and 3CD proteases.  The inclusion 
of the 3D gene with the 3C depends on the specific virus as some viruses like poliovirus and 
coxsackievirus need the 3D to efficiently cleave the P1 polyprotein, while in contrast FMDV 
can efficiently cleave the P1 independently 92.  Baculovirus constructs with this approach 
have produced VLPs that stimulate immune responses and the production of neutralizing 
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antibodies in mice, guinea pigs, swine, cattle, and macaque monkeys 8,61,62,64,65,93-97.  Humoral 
immune responses induced by EV71 VLPs in mice and macaque monkeys included high 
neutralizing antibody titers, while Th1 and Th2 immune responses have produced high levels 
of IFN-γ, IL-2 and IL-4 64,94.  Neutralizing antibodies have also been shown to protect against 
lethal challenges by passive transfer of antisera and active immunization in mice for EV71, 
CVA6 and CVA16 infections through baculovirus-expressed VLPs 64,93,95.   
 Virus-like particles have also been produced by simultaneous transfection of insect 
cells with two baculovirus constructs encoding recombinant P1 and 3CD proteins separately 
for EV71 9,98,99 .  In 2003, EV71 VLPs resembling native EV71 aggregates were constructed 
for the first time using this method 98.  A study was then conducted for EV71 VLPs 
comparing two separate recombinant baculoviruses expressing P1 and 3CD independently to 
that of a single recombinant baculovirus co-expressing P1 and 3CD 9. The EV71 VLPs with 
the single recombinant baculovirus co-expressing P1 and 3CD produced more VLPs than that 
expressed via simultaneous infection with two separate baculoviruses expressing the P1 or 
3CD respectively 9.  Nonetheless, the VLPs from simultaneous infection with two separate 
baculoviruses produced neutralizing antibodies against different strains of EV71 in 
immunized mice similar to the co-expressed P13CD baculovirus constructs 99.  Another 
construct design used the BEVS and codon-optimized FMDV genes for insect cells.  The 3C 
protease was omitted and instead the 2A protease was utilized to cleave capsid proteins VP1 
and VP3 to produce VLPs along with VP0 expressed under a second promoter 100.     
 These studies prove that VLP assembly of picornaviruses can occur in the BEVS.  
However, no research has been published to date on attempts of SVV recombinant capsid 
protein expression with VLP assembly.  The BEVS is ideal for assembling SVV VLPs 
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because of its efficiency of expressing complex, multi-protein VLPs.  The BEVS also allows 
for rapid modifications of the genome to evaluate different variations.  Exploiting the 
knowledge gained from these previous works, the BEVS was utilized to engineer baculovirus 
constructs encoding SVV viral proteins.  These constructs were evaluated for expression of 
SVV recombinant capsid proteins and VLP assembly.  The findings of this research may 
further support picornavirus VLP assembly strategies and understanding of SVV viral capsid 
formation. 
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CHAPTER 3:  EXPRESSION AND PURIFICATION OF SENECA VALLEY VIRUS 
RECOMBINANT CAPSID PROTEINS FROM BACULOVIRUS-INFECTED INSECT 
CELLS 
 
Introduction 
The increase of clinical manifestations of SVV in the last three years and the 
resemblance to FMD has increased biosecurity concerns in regions where FMDV is not 
present.  Negligence in reporting clinical signs of SVV could provide foreign vesicular 
diseases an opportunity to spread rapidly through swine herds before being detected.  A 
vaccine against SVV is one possibility to reduce this dangerous threat to the US pork 
industry.   
Baculovirus-expressed picornavirus VLPs have demonstrated several key traits that 
are required for efficacious vaccines.  Baculovirus-expressed picornavirus VLPs have 
elicited virus-specific neutralizing antibodies, cellular and humoral immune responses, 
passive immunity and protection against virus challenge 62, 63, 71, 75-79.  A VLP based vaccine 
utilizing the BEVS could provide an effective and safe vaccine with DIVA potential for 
SVV.  By decreasing the prevalence of vesicle presentation caused by SVV, the vaccine 
could support rapid identification of devastating foreign diseases of swine exhibiting similar 
clinical signs. 
Seneca Valley virus encodes a single polyprotein that contains structural proteins 
VP1, VP2, VP3 and VP4 that create the viral capsid when processed into individual subunits 
by viral proteases, as in many other picornaviruses 11.  An empty viral capsid structure has 
been identified for several picornaviruses during the native infection process and has been 
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shown to be stable under certain conditions 86,101.  Virus-like particles that are near identical 
to the native empty viral capsids have been assembled with the BEVS.  Based on previous 
published literature of picornavirus VLP assembly, an initial design for SVV baculovirus 
constructs was modeled after FMDV constructs 84,97.  The transfer vector contained the SVV 
P1 region, portions of 2B and 3B, and the self-cleaving proteases 2A and 3C.  The herein 
described SVV baculovirus constructs were evaluated for VLP formation to determine their 
suitability to serve as potential recombinant subviral vaccine candidates.  
 
Materials and Methods 
Design and construction of SVVP13C recombinant capsid protein plasmids  
Two gene sequences were designed and ordered in the pUCIDT-Amp vector from 
Integrated DNA Technologies, Inc. (IDT) based on the resultant consensus sequence of SVV 
26, SVV 27, SVV 29, SVV 30 and SVV 49 received from Kansas State University.  The 
SVVP13C gene ordered was native consensus sequence of the full length P1 polyprotein with 
2A and partial 2B and 3B sequences connecting the P1 polyprotein and 3C self-cleaving 
protease.  The SVVP13C-CO gene ordered had the P1, 2A and 2B sequences codon-
optimized for Sf9 insect cells using the IDT Codon Optimization Tool while the 3B and 3C 
remained as native sequences.  Both genes contain a Kozak sequence before the start codon, 
as well as BamHI and NotI restriction sites at the 5’ and 3’ ends, respectively.  The 
SVVP13C and SVVP13C-CO gene inserts were excised from pUCIDT-AMP-SVVP13C and 
pUCIDT-AMP-SVVP13C-CO plasmids by BamHI and NotI digestion, respectively, and 
ligated into the pVL1393 vector (Fig. 3).   
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Design and construction of WSSV sIRES-split his-tagged SVVP1 with SVV3C 
recombinant capsid protein plasmids  
PCR amplification was performed with the SVVP13C and SVVP13C-CO genes in the 
pUCIDT-Amp vectors to amplify the SVVP1 or SVVP1CO sequence with a C-terminal 6x-
His tag and the SVV3C sequence (See Table 1 for primers).  The SVVP1, SVVP1-CO and 
SVV3C PCR products were independently ligated into pCR-BluntII-TOPO.  The SVV3C 
insert was excised from pCR-BluntII-TOPO-SVV3C by SpeI and SacI digestion and ligated 
into the pORB vector following the WSSV sIRES site to generate pORB-MCS1-sIRES-
SVV3C.  Next, SVVP1-His or SVVP1CO-His sequences purified from pCR-BluntII-TOPO 
were ligated into the pORB-MCS1-sIRES-SVV3C plasmid.  The pORB-SVVP1-His-sIRES-
SVV3C and pORB-SVVP1CO-His-sIRES-SVV3C were submitted to ISU DNA Facility for 
sequencing (Fig. 4).  The pORB-SVVP1-His-sIRES-SVV3C had two nucleotide substitutions 
in its insert sequence.  One nucleotide substitution was in the VP1 at position 2404 from G to 
T that caused a polar to polar amino acid change of glycine to cysteine.  The second 
substitution was in the SVV 3C sequence of both plasmids submitted for sequencing at 
nucleotide position 133 from C to A causing a non-polar to non-polar amino acid change of 
leucine to isoleucine.  These changes are not expected to alter the predicted structure based 
on analysis with the MOE program (Molecular Operating Environment [MOE], 2013.08; 
Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, 
Canada, H3A 2R7, 2017).   
Design and construction of SVVP13C VP3/VP1 and SVVP13CD recombinant capsid 
protein plasmids  
Primers were designed to mutate the VP3/VP1 cleavage site of the SVV P1 sequence 
in pUCIDT-AMP-SVVP13C from FH/ST to PQ/GV (See Table 2 for primers) using the 
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Lightning Quik Site Directed Mutagenesis kit (Stratagene).  The pUCIDT-AMP-SVVP13C 
VP3/VP1 contained the correct mutation sequence and the SVVP13C VP3/VP1 insert was 
excised and ligated into the pVL1393 vector to produce pVL1393-SVVP13C VP3/VP1 (Fig. 
5).  Sequence results matched the expected DNA map except for a single point mutation in 
VP2 at position 946, changing G to T.  The nucleotide substitution resulted in a non-polar to 
non-polar, aromatic amino acid change from valine to phenylalanine.  Evaluation of the 
valine to phenylalanine amino acid change with MOE suggested there would be minimal 
effect on the expected capsid structure.  The second construct designed ligated the SVV3D 
sequence to the C-terminal end of the SVV3C sequence by overlap extension PCR (OE-PCR) 
of a SVV3D PCR product from cDNA to a SVVP13C PCR product amplified from pUCIDT-
AMP-SVVP13C to generate pCR-BluntII-TOPO-SVVP13CD (See Table 2 for primer 
sequence).  Due to an internal BamHI restriction site in the SVV3D sequence, BamHI 
digestion of the SVVP13CD insert resulted in two pieces, which were subsequently ligated 
into the pVL1393 vector creating pVL1393-SVVP13CD (Fig. 5).   
Expression of the SVV recombinant capsid protein constructs in insect cells 
The recombinant SVV capsid constructs in the pVL1393-based plasmids were co-
transfected with FlashBAC ULTRA (FBU) baculovirus DNA into Sf9 cells, whereas the 
pORB-based plasmids were co-transfected with BaculoGold baculovirus DNA into Sf9 insect 
cells.  Both sets of co-transfections used ESCORT transfection reagent per manufacturer’s 
instructions.  Cell culture supernatants from the transfected Sf9 cells were harvested and 
clarified by centrifugation at 1,000xg for 5 min to pellet the cellular debris.  The clarified 
supernatant was collected, 0.2 µM-filtered and stored as the P1 transfection harvest.  Sf9 
insect cells were used to generate P2 stocks, and the P2 stocks were then used to generate P3 
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and P4 amplifications of the SVV constructs for protein expression evaluations in SF+ insect 
cells.  The SF+ insect cell line is a derivative of Spodoptera frugiperda insect cells.  
Baculovirus-infected SF+ cells were harvested and clarified at 10,000xg for 10 min at 4°C.  
The cultures of baculovirus-infected SF+ cells were sampled daily to monitor total cells/mL, 
viable cells/mL, percent viability and cell diameter by Vi-Cell analysis.  Amplifications were 
harvested when viability was ≤ 30% viability or when viable cells were ≤ 1x106 cells/mL.  
Additional one mL daily samples were collected to evaluate the progression of protein 
expression during infection and were processed as described above.  Collected supernatant 
and cell pellet samples were stored at -70°C until evaluation. 
Lysis of insect cell pellets to separate soluble and insoluble fractions 
SF+ insect cell culture samples were centrifuged to pellet the cells after which the 
media was removed and the cell pellets were frozen until lysis.  Pellets were re-suspended in 
lysis buffer containing the following: 20mM Tris, 1% Triton X-100, Protease Inhibitor 
Cocktail for His-tagged Proteins (10μL/mL) and Benzonase (250 units/mL) in de-ionized 
water with a pH of 7.4.  The re-suspended insect cell lysates were vortexed for 10 sec, 
incubated at room temperature for 5 min, vortexed again for 10 sec than centrifuged at 
19,090xg for 10 min at 4°C to pellet insoluble material.  The soluble lysates were separated 
from the insoluble fractions and stored in tubes at -70°C.   
Purification of SVV recombinant capsid proteins 
Supernatant harvests containing the expressed recombinant SVV capsid proteins were 
0.2µM-filtered, dispensed into ultracentrifuge tubes, and centrifuged at 100,000xg for two 
hours at 4°C to pellet protein and possible VLPs.  The clarified supernatant was carefully 
decanted and the pelleted material was re-suspended in TBS and stored at 4°C.  
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Discontinuous 10% - 60% sucrose gradients were used to further purify recombinant SVV 
capsid proteins for the respective constructs.  The respective re-suspended materials were 
added to the top of the gradient and centrifuged at 100,000xg for two hours at 4°C.  Fractions 
from the sucrose gradients were collected equally into tubes (with fraction 1 starting at the 
top of the gradient surface) and stored at 4°C. 
SDS-PAGE & Western blot 
SDS-PAGE was performed using the NuPAGE electrophoresis system and 4-12% 
Bis-Tris MES mini gels.  Samples were separated under reducing conditions using 0.05M 
DTT at 175V for the appropriate time.  Gels were stained for total protein using an eStain 
2.0 Protein Staining Device or transferred to nitrocellulose membranes using the iBlot system 
for Western blots.  Western blots were performed with α-SVV peptide rabbit polyclonal 
antibodies (α-SVV VP1-2, α-SVV VP2-2, and α-SVV VP3-1, varying dilutions) and goat anti-
rabbit peroxidase-labeled secondary antibody (1:500) by the Snap ID method, utilizing 
negative control baculovirus antigen in the antibody diluent, and developed using TMB 
membrane peroxidase substrate.   
Dialysis and concentration of purified SVV recombinant capsid proteins 
Sucrose gradient fractions containing the recombinant protein as determined by 
Western blot were pooled together and dispensed into 10,000 molecular weight cut-off 
(MWCO) or 50,000 MWCO cellulose membrane dialysis cassettes.  The dialysis cassette was 
placed in 3.5L of TBS with a magnetic stir bar, covered, and placed on a stir plate at 4°C for a 
minimum of 6hrs.  The dialysis cassette was then placed into a fresh beaker of 3.5L of TBS, 
and further dialyzed by stirring overnight or longer.  The sample was removed from the 
dialysis cassette and concentrated, if needed, depending on the volume of the dialyzed 
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sample.  Concentration was performed using a size-exclusion filter unit and centrifugation 
according to manufacturer’s directions until desired sample volume was achieved.   
Electron microscope imaging 
The sucrose gradient-purified and dialyzed recombinant SVV capsid proteins were 
evaluated by transmission electron microscopy (TEM) at the USDA National Animal Disease 
Center (NADC) with Judi Stasko for the visualization of VLPs.  The expected size of the 
icosahedral viral capsid for native SVV is approximately 27nm in diameter.   
 
Results 
Expression of SVV capsid proteins in baculovirus-infected insect cells 
The BaculoFBU/SVVP13C and BaculoFBU/SVVP13C-CO constructs were used to 
infect SF+ cells, and samples were collected to evaluate the expression of SVV capsid 
proteins.  Protein bands of expected sizes for VP1, VP2 and VP3 capsid subunits were 
detected by Western blot with α-SVV P1 subunit-specific antibodies in the supernatant (Fig. 
6).  The recombinant proteins expressed from the baculovirus-infected insect cells were also 
similar in size to native SVV capsid proteins.  Interestingly, an additional protein band of 
~55kDa was detected in the α-SVV VP1 and α-SVV VP3 Western blots.  The ~55kDa band 
was not detected in the native SVV antigen sample or the negative control.  The presence of 
the additional protein of ~55kDa suggests that it may comprise an uncleaved VP3-VP1 
protein product and merits further investigation.  Figure 6 also provides a comparison of SVV 
capsid protein expression levels between the native (A) and the codon-optimized (B) SVV 
DNA sequences in baculovirus-infected SF+ cells.  Based on these Western blots, there was 
no readily apparent difference in SVV capsid protein expression levels between the codon-
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optimized BaculoFBU/SVVP13C-CO and the native BaculoFBU/SVVP13C. 
The SVV baculovirus constructs that were WSSV sIRES-split his-tagged SVVP1 
with the 3C protease placed behind the sIRES did not produce detectable SVV capsid subunit 
proteins.  Consequently, this set of constructs was not further evaulated.   
BaculoFBU/SVVP13C-derived SVV capsid subunits do not form VLPs  
As a control to be used in determining the expected mobility of BaculoFBU/ 
SVVP13C-derived SVV capsid proteins in a sucrose gradient, pelleted native SVV virus was 
separated on a sucrose gradient and analyzed by Western blot (Fig. 7A).  The majority of 
native SVV subunit proteins were detected in fractions five and six after sucrose gradient 
purification for native SVV.  It was anticipated that if VLPs were formed in the baculovirus-
infected SF+ cells they would present in a similar or slightly higher range of collected 
gradient fractions when compared to that of native SVV. 
Harvest supernatant from the BaculoFBU/SVVP13C construct was also processed 
and subjected to sucrose gradient purification.  Western blots of the sucrose gradient fractions 
only detected a small portion of the recombinant SVV VP2 capsid protein in sucrose fraction 
one (Fig. 7B).  VP1 and VP3 were not detected in the sucrose fractions, although a faint 
protein band at ~55kDa, thought to be uncleaved VP3-VP1, was detected throughout the 
sucrose fractions by α-SVV VP1 in the Western blot.  Recombinant SVV capsid proteins 
were not detected in fractions five and six in contrast to the detection of expected proteins 
from native SVV.  These results suggest that the capsid subunit proteins expressed in 
BaculoFBU/SVVP13C-infected insect cells do not form VLPs.   
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Modification of VP3/VP1 cleavage site 
Previous research identifying the amino acids at the cleavage sites of cardioviruses, 
with which SVV shares the most similarity, indicated the predicted SVV VP3/VP1 cleavage 
site His/Ser was unusual compared to the cleavage site Gln/Gly shared amongst cardioviruses 
such as EMCV and Theilovirus 6.  The SVV VP3/VP1 cleavage site is also atypical of the 
primary picornavirus 3C protease cleavage sites Gln/Gly, Gln/Ser and Glu/Asn 4,6,102-104.  
Therefore, a mutation was made at the VP3/VP1 interface in the BaculoFBU/SVVP13C 
construct to exchange the His/Ser amino acid sequence for Gln/Gly generating the 
BaculoFBU/SVVP13C VP3/VP1 construct. 
This new construct was transfected into Sf9 cells and the resulting baculovirus was 
evaluated in protein expression assessments in a similar fashion as conducted with the 
BaculoFBU/SVVP13C construct (Fig. 8).  A protein band at the expected full length of the 
SVV P1 polyprotein, ~95kDa, was detected in the BaculoFBU/SVVP13C VP3/VP1-infected 
insect cell harvest supernatants.  These supernatant samples also contained the recombinant 
capsid proteins VP1, VP2 and VP3 recognized by their respective antibody.  Detection of the 
putative uncleaved VP3-VP1 protein at ~55kDa and cleaved subunits of VP3 and VP1 were 
of similar proportion as was observed in BaculoFBU/ SVVP13C supernatant Western blots.   
Additionally, Western blot evaluations of the sucrose gradient fractions from the 
harvest supernatant (Fig. 9) were comparable to the results of BaculoFBU/SVVP13C.  The α-
SVV VP2 Western blot detected the recombinant SVV VP2 capsid protein throughout the 
sucrose fractions with the majority in fractions one and nine.  Subunit VP1 and VP3 proteins 
were not detected in the sucrose fractions.  Although a protein band at ~55kDa that is 
possibly the VP3-VP1 uncleaved proteins was detected throughout the sucrose fractions of 
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the α-SVV VP1 Western blot and in sucrose fractions one and nine of the α-SVV VP3 
Western blot.  All three Western blots had protein bands detected in the very last sucrose 
fraction that appeared similar to the starting sample of the sucrose gradient.  We conclude 
from these Western blot evaluations that the mutation of the cleavage sequence from His/Ser 
to Gln/Gly had no effect on the presence of the ~55kDa band hypothesized to be uncleaved 
VP3-VP1 proteins.  Compared to the original construct, there were no increases in the 
amounts of subunit VP3 and VP1 proteins detected and no VLP formation was observed. 
Modification of 3C protease 
Enteroviruses which also belong to the Picornaviridae family have been shown to 
utilize the 3CD protease, a precursor to 3C, for efficient cleavage of capsid proteins in the 
BEVS and other expression systems 9,70,105,106.  The BaculoFBU/SVVP13CD was designed to 
include the 3D gene after 3C to assess cleavage of recombinant capsid proteins compared to 
3C protease alone in the original BaculoFBU/SVVP13C baculovirus construct. 
BaculoFBU/SVVP13CD was expressed in SF+ cells, and the supernatant harvest was 
evaluated by Western blot (Fig. 10).  Results similar to the previous protein assessments were 
observed by the detection of individual VP1, VP2 and VP3 proteins.  The suspected 
uncleaved VP3-VP1 protein at ~55kDa was also present in the α-SVV VP1 and α-SVV VP3 
Western blots. 
The Western blots of the BaculoFBU/SVVP13CD sucrose gradient fractions showed 
the majority of the SVV capsid proteins aggregated and pelleted at the bottom of the gradient 
(Fig. 11).  These results were similar to the BaculoFBU/SVVP13C VP3/VP1 sucrose fraction 
evaluations.  In contrast, these results exhibited monomeric SVV VP1, VP2 and VP3 capsid 
subunit proteins present in sucrose fractions 1 and 2.  In addition, the VP1 and VP2 proteins 
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were detected throughout the sucrose fractions.  Detection of SVV VP1 and VP2 proteins 
throughout the sucrose fractions suggested the possibility of VLP formation. 
EM imaging of purified samples containing recombinant capsid proteins 
Despite unclear results from the sucrose gradient evaluation of each construct, 
fractions expected to contain VLPs were evaluated by TEM at the USDA NADC.  Pooled 
sucrose fractions from supernatant harvests BaculoFBU/SVVP13C and BaculoFBU/ 
SVVP13CD were dialyzed in TBS and concentrated in preparation for TEM imaging.  The 
sample preparations contained high levels of background particulate making it difficult to 
visualize VLPs clearly by TEM negative staining.  Some spherical shapes were sparsely 
evident in the BaculoFBU/SVVP13CD pooled sucrose fractions that were similar in size to 
that expected of SVV VLPs.  However, insufficient numbers of putative VLP structures 
made it difficult to confirm their existence.  Representative TEM images are shown in the 
appendix. 
Investigating inside the SF+ insect cells for VLP assembly 
One hypothesis as to why the individual recombinant SVV viral capsid proteins were 
detected in the supernatant, but did not form VLPs is that the VLPs might have disassociated 
shortly after release into the supernatant.  The dissociation could be due to the low pH of the 
insect cell media or degradation by proteases released during the baculovirus infection.  To 
test this hypothesis, cell pellet samples from Day 3 of BaculoFBU/SVVP13C, 
BaculoFBU/SVVP13C VP3/VP1 and BaculoFBU/ SVVP13CD infections were lysed in 
physiological pH buffer.  The soluble protein fractions were obtained from the lysed material 
for evaluation of recombinant SVV subunit proteins by Western blot (Fig. 12).  Day 3 was 
chosen because viral infection was actively ongoing, as indicated by swelling of the cells, but 
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the viability of the cells was still relatively high as many of the baculovirus-infected cells had 
not yet lysed.   
As expected, there were detectable levels of subunit capsid proteins VP1, VP2 and 
VP3 in the Day 3 soluble fractions.  An ~55kDa band suspected to be uncleaved VP3-VP1 
proteins was also detected in the α-SVV VP1 and α-SVV VP3 Western blots as observed in 
previous Western blot evaluations.  Day 3 soluble fraction samples were sucrose gradient 
purified and evaluated by Western blot to observe if VLPs were present in the cells before 
lysis (Fig. 13). 
The sucrose fractions from the Day 3 soluble fractions had comparable results with 
the supernatant harvest sucrose fractions from insect cells infected with BaculoFBU/ 
SVVP13C, BaculoFBU/SVVP13C VP3/VP1 and BaculoFBU/SVVP13CD, respectively.  
The SVV recombinant capsid proteins were detected mostly in fractions one and two and/or 
pelleted to the bottom suggesting the SVV subunit proteins inside the insect cells do not form 
VLPs prior to cell lysis.  Transmission electron microscopy was performed on the pooled 
sucrose fractions 2-4 of BaculoFBU/SVVP13CD Day 3 soluble sample and the pooled 
sucrose fractions 2-3 of BaculoFBU/SVVP13C VP3/VP1 Day 3 soluble sample (See 
Appendix for images).  Results were inconclusive for VLP assembly for both samples due to 
high levels of background particulate present.   
 
Discussion 
There has been an increase in recent years in SVV cases reporting SIVD clinical signs 
that are indistinguishable from foreign animal diseases such as FMD and SVD.  In response 
to the increased detection of clinical manifestations of SVV, a VLP-based vaccine would be 
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very useful.  It could deter complacency in reporting SVV vesicles and foreign swine 
vesicular diseases entering the US undetected.  There is no published work to date on VLP 
assembly for SVV; therefore, the initial SVV baculovirus construct was designed based on 
successful VLP constructs produced for other picornaviruses 9,62,64,91,98,107.  However, due to 
ineffective VLP formation in the initial construct, modifications were introduced to explore 
alternative constructs for VLP assembly.  Baculovirus constructs encoded the full-length 
SVV P1 polyprotein, partial sequences of 2B and 3B, and the 2A and 3C proteases.  The 
SVV 3C protease was incorporated for self-cleavage of the expressed P1 polyprotein into 
individual protein subunits.  Recombinant SVV capsid proteins VP1, VP2 and VP3 were 
expressed to some extent as fully cleaved proteins and detected by α-SVV peptide antibodies 
in Western blot.  However, VLPs were not detected based on sucrose gradient purification 
and EM imaging.   
An interesting discovery in BaculoFBU/SVVP13C Western blots detected with α-
SVV VP1 and α-SVV VP3 antibodies was another protein band identified at approximately 
55kDa that was generated in the baculovirus-infected SF+ cells, but not in the native virus.  
The 55kDa band corresponds to the expected size of uncleaved VP3-VP1 proteins.  It was not 
detected in the α-SVV VP2 Western blot further leading us to suspect it may be a protein 
specific to VP3 and VP1.  This protein band may be an indication as to why VLP formation 
is hindered in the baculovirus-infected insect cells.   
The additional baculovirus constructs were designed to evaluate the cleavage site of 
VP3 and VP1 in attempts to increase levels of cleaved VP1 and VP3 subunit proteins.  
Western blot results determined there was no change in the amount of the individual 
expressed VP3 and VP1 proteins among any of the baculovirus constructs.  In addition, the 
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approximate 55kDa protein band suspected as the VP3-VP1 fusion protein was still detected 
in the Western blots with α-SVV VP1 and α-SVV VP3 antibodies, and it did not appear to 
change in the amount expressed.   
  Specifically, the 55kDA protein band suspected to be VP3-VP1 uncleaved proteins 
was evaluated for its decreased detection with corresponding expectations of increased 
detection of cleaved VP3 and VP1 capsid proteins.  Conversely, the 55kDa band was still 
detected in Western blots at comparable levels as the original SVV baculovirus construct.  N-
terminal sequencing or mass spectrometry could be performed to confirm if the 55kDa band 
is indeed uncleaved VP3-VP1 proteins. 
In Western blot evaluations of sucrose gradient fractions, the recombinant SVV 
capsid proteins were detected in the first few fractions and/or in the last fraction of the 
gradient.  The presence of proteins in these fractions led us to determine that they remained 
as non-associated monomers or formed large aggregates indicative of misfolded or 
misassembled proteins, respectively.  These findings could also be the result of an 
insufficient amount of subunit proteins being expressed resulting in unmet threshold limits 
for capsid protein concentrations required for VLP formation 108-110.   
An aspect that was not evaluated in this research is the impact of picornaviral 3C 
proteases on host cellular proteins.  Some 3C proteases have been shown to cleave important 
host cell proteins leading to apoptosis 102.  For example, 3C proteases cleave translation 
initiation factors that control cell survival.  These effects of innate 3C activity could affect 
baculovirus-infected insect cells as well and hinder SVV gene expression in the BEVS 102,111.  
In the full SVV genome, the SVV 3C protease targets twice as many predicted cleavage sites 
than the number of cleavage sites present in the baculovirus constructs 6.  Therefore, normal 
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expression of the 3C protease required in a native infection to cleave all these sites may not 
be necessary in baculovirus transfection.  The potential excess 3C protease could be 
prompting proteolytic activity of SF+ proteins in turn affecting capsid protein expression and 
VLP formation.  If 3C-based proteolytic activity within the SF+ cells is reducing capsid 
protein expression, the present expression levels may not be enough to meet the threshold for 
efficient SVV VLP assembly.  Research into SVV 3C and 3CD protease expression levels 
using the BEVS should be conducted to get a better understanding of their effect on protein 
expression in baculovirus-infected insect cells. 
Previous research with similarly designed FMDV constructs revealed cell toxicity 
attributed to 3C expression.  Results showed a decrease in FMDV 3C protease expression led 
to increased amounts of cleaved capsid proteins and VLP formation 107,111.  In a separate 
experiment, a dual promoter baculovirus vector expressing the EV71 P1 region under the 
polyhedrin promoter and the 3C protease under a less active promoter also improved VLP 
yields 112.  This study suggests reducing the level of 3C expression in a dual promoter-based 
baculovirus vector could have improved EV71 capsid protein production due to reduced 
competition between P1 and 3C expression when under the same promoter.  This prospect is 
in addition to the 3C protease causing cell toxicity as stated in the FMDV study.  In 
comparison to the EV71 dual promoter baculovirus vector results, an alternate study with 
FMDV investigated strategies for FMDV 3C expressed under the same or separate promoter 
as the P1-2A sequence in the BEVS.  The results showed higher recombinant protein 
expression in the single-promoter vector compared to the dual-promoter vector 84.  However, 
the FMDV 3C was placed under the p10 promoter, which has been shown to be active a few 
hours earlier than the polyhedrin promoter and could have led to decreased protein synthesis 
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due to its deleterious effects on host cells, as discussed previously 113.  An alternate strategy 
to avoid the use of 3C protease could be to utilize the 2A protease for cleaving the P1 
polyprotein into the individual capsid proteins.  A study generating FMDV VLPs utilizing 
only the 2A protease has proven to be successful for VLP formation 100.    
  Further evaluations need to be performed to determine if the protein band at 
approximately 55kDa is indeed a VP3-VP1 fusion protein.  In addition, performing SVV3C 
evaluations would give a better idea of SVV3C protein expression inside the cell during 
infection and its release into the supernatant.  The baculovirus system has the potential of 
creating a SVV VLP, but determining why the viral capsid proteins do not readily form VLPs 
in baculovirus-infected insect cells requires further investigations. 
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CHAPTER 4: CONCLUSION 
Recent SVV outbreaks have prompted increased interest and research to better 
understand the virus and its role in SIVD.  Although SVV is not a severely debilitating 
disease, the risk of foreign swine vesicular diseases entering our borders undetected due to 
unreported SVV clinical signs would have a devastating impact on the swine industry.  A 
vaccine would reduce the occurrence of SVV vesicles and support rapid identification of 
foreign swine vesicular diseases necessary to maintain biosecurity. 
The BEVS has been used to produce several licensed vaccine products for humans 
and animals.  The VLP assembly of many picornavirus proteins has also been proven using 
the BEVS.  The BEVS would be an ideal platform to provide a rapid method for producing a 
safe and efficacious VLP-based SVV vaccine. 
The research performed within this thesis produced SVV capsid proteins detected by 
specific antibodies in Western blot.  This was similar to findings of many other baculovirus-
expressed recombinant capsid proteins of picornaviruses 9,64,91,98.  However, the SVV capsid 
proteins produced did not go on to form a higher ordered VLP structure.  The lack of SVV 
VLP formation could be due to several factors and indicates that further research is warranted 
to better understand the deficiencies in the SVV VLP assembly process in the BEVS. 
Many common viruses of the Picornaviridae family such as poliovirus, 
coxsackievirus A, enteroviruses, swine vesicular disease virus and foot-and-mouth disease 
virus have proven VLP assembly in the research stage.  Although, currently there are no 
VLP-based licensed vaccines for these viruses demonstrating further research efforts are 
needed to overcome herein described hurdles.  The research conducted for SVV VLP 
assembly provides increased understanding of the capsid formation of picornaviruses and 
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differences in efficiency of VLP formation.  Even though SVV VLP assembly did not occur, 
the recombinant capsid proteins expressed could be purified and evaluated as vaccine 
antigens.  Additionally, they provide value as reagents in neutralization assay, ELISA, and 
serological detection of SVV. 
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APPENDIX: FIGURES, TABLES & EM IMAGES 
 
 
Fig. 1.  Genome structure of picornavirus and polyprotein processing 5. 
 
 
 
 
 
 
Fig. 2.  Phylogenetic trees of the whole genome of SVA.  Strains are indicated according to country of origin: 
Brazil (BRA), Canada (CAN), China (CH), and the USA 11. 
42 
 
 
 
 
 
 
Fig. 3.  Seneca Valley virus baculovirus construct designs.  SVVP13C and SVVP13C-CO (codon 
optimized) genes in the pVL1393 transfer vector for the baculovirus expression vector system. 
 
 
 
 
 
 
 
Fig. 4.  WSSV sIRES-split his-tagged SVVP1 with SVV3C baculovirus construct designs.  SVVP1-
His-sIRES-SVV3C and SVVP1CO-His-sIRES-SVV3C (codon optimized) genes in the pVL1393 
transfer vector for the baculovirus expression system. 
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Fig. 5.  SVVP13C VP3/VP1 and SVVP13CD baculovirus construct designs.  SVVP13C VP3/VP1 
construct design (A) to mutate the VP3/VP1 cleavage site and SVVP13CD construct design (B) 
adding the 3D sequence to the C-terminal end of 3C. 
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Fig. 6.  SVV Recombinant Capsid Protein Expression.  Western blots of BaculoFBU/SVVP13C (A) and 
BaculoFBU/SVVP13C-CO (B) supernatant samples compared to native SVV antigen detected with α-SVV 
VP1, α-SVV VP2 and α-SVV VP3 cross-adsorbed rabbit polyclonal antibodies. Lane A- Protein Standard, Lane 
1-SVV Baculo Harvest Supernatant Lane 2-SVV Antigen and Lane 3-Baculo Harvest Supernatant Neg. 
Control.  Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, VP2= ~32kDA, VP3= ~26kDA 
 
 
  
 
Fig. 7.  Western blots of native SVV virus sucrose fractions (A) and BaculoFBU/SVVP13C sucrose fractions 
(B) with α-SVV VP1, α-SVV VP2 and α-SVV VP3 rabbit polyclonal antibodies.  Lane A- Protein Standard, 
Lanes 1-10- Sucrose fractions 1-10, N- BaculoFBU/No Insert Negative Control, P- Positive Control Native 
inactivated SVV and S- Starting sample for sucrose gradient.  
Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, VP2= ~32kDA, VP3= ~26kDA 
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Fig. 8.  Western blots of BaculoFBU/SVVP13C and 
BaculoFBU/SVVP13C VP3/VP1 supernatant harvests with α-
SVV VP1 antibody (top row) and α-SVV VP3 (bottom row) 
rabbit polyclonal antibodies.  Lane A-Protein Standard, Lane 
1-SVV Baculo Harvest Supernatant, Lane 2-SVV Antigen and 
Lane 3-Baculo Harvest Supernatant Neg. Control.  Expected 
Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, 
VP3= ~26kDA, VP3-VP1= ~56kDa 
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Fig. 9.  Western blots of BaculoFBU/SVVP13C VP3/VP1 sucrose fractions with α-SVV VP1, α-SVV VP2 and 
α-SVV VP3 rabbit polyclonal antibodies.  Lane A-Protein Standard, N= BaculoFBU/No Insert Negative 
Control, P= Positive Control native inactivated SVV, S= SVVP13C VP3/VP1 pellet re-suspended in TBS and 
Lane 1-9 = Sucrose Fractions 1-9. 
Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, VP2= ~32kDa and VP3= ~26kDA 
 
 
 
 
 
 
Fig. 10.  Western blots of BaculoFBU/SVVP13CD Supernatant 
Harvest detected with α-SVV VP1, α-SVV VP2 and α-SVV VP3 rabbit 
polyclonal antibodies.  Lane A-Protein Standard, Lane 1-SVV Baculo 
Harvest Supernatant Lane 2-SVV Antigen and Lane 3-Baculo Harvest 
Supernatant Neg. Control.  
Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, 
VP2= ~32kDA and VP3= ~26kDA 
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Fig. 11.  Western blots of BaculoFBU/SVVP13CD sucrose fractions with α-SVV VP1, α-SVV VP2 and α-SVV 
VP3 rabbit polyclonal antibodies.  Lane A-Protein Standard, N= BaculoFBU/No Insert Negative Control, P= 
Positive Control Native inactivated SVV, S= SVVP13CD pellet re-suspended in TBS and Lane 1-10 = Sucrose 
Fractions 1-10. 
Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, VP2= ~32kDa and VP3= ~26kDA 
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Fig. 13.  Western blots of sucrose fractions of Day 3 Soluble BaculoFBU/SVVP13C, BaculoFBU/SVVP13CD 
and BaculoFBU/SVVP13C VP3/VP1 with α-SVV VP1, α-SVV VP2 and α-SVV VP3 rabbit polyclonal 
antibodies.  Lane A- Protein Standard, Lane B-SVV Baculo Harvest Supernatant Lane C-SVV Antigen and 
Lane D- Supernatant Baculo Neg. Control.  Lanes 1-10- Sucrose Fractions 1-10 and Lane 11- SVVP13C 
VP3/VP1 Starting Pellet.  Expected Band Sizes: Full Length SVV P1= ~95kDa, VP1 = ~29kDa, VP2= 
~32kDA, VP3= ~26kDA and SVV VP1+VP3= ~56kDa. 
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Table 1.  Primer Sequences for SVVP1-His-SVV3C and SVVP1CO-His-SVV3C 
Primer Sequence (5’ - 3’) Lot # 
P3219012A  
(SVVP1 Fwd) GGATCCGCCACCATGGGTAATGTTCA 3219-013A 
P3219039A 
(SVVP1 His Rev) 
GCGGCCGCTCAGTGGTGGTGGTGGTGGTGTTGCATCA
GCATCTTTTGCTTGTAGCTGC 3219-042A 
P3219012C 
(SVVP1-CO Fwd) GGATCCGCCACCATGGGCAACG 3219-013C 
P3219039B 
(SVVP1-CO His Rev) 
GCGGCCGCTCAGTGGTGGTGGTGGTGGTGTTGCATAA
GCATCTTCTGTTTATAGCTACGG 3219-042B 
P3219012E 
(SVV3C Fwd) ACTAGTATGCAGCCCAACGTGGACATGGGCTTT 3219-013E 
P3219039C 
(SVV3C Rev) GAGCTCTCATTGCATTGTAGCCAGAGGCTCACCGA 3219-042C 
 
 
 
Table 2.  Primer Sequences for SVVP13C VP3/VP1 and SVVP13CD 
Primer Sequence (5’ - 3’) Lot # 
P3219165A 
(VP3/VP1 Fwd) CTTCCTACGTGCCTCAGGGGGTTGACAACGCCGAGACTGGG 3219-168A 
P3219165B 
(VP3/VP1 Rev) CCCAGTCTCGGCGTTGTCAACCCCCTGAGGCACGTAGGAAG 3219-168B 
P3219166A 
(SVV3D Fwd) TACAATGCAAGGACTGATGACTGAGCTAGAGCCTG 3219-171A 
P3219166B 
(SVV3C Rev) TCAGTCATCAGTCCTTGCATTGTAGCCAGAG 3219-171B 
P3219166C 
(SVV3D Rev) GCGGCCGCTCAGTCGAACAAGGCCCTCCATCT 3219-171C 
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